Stryker Stock News

This medical devices giant has a habit of crushing the market.

Las Vegas, USA, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Ureteroscope Market Anticipated to Witness a Significant CAGR of 5.47% by 2026, Estimates DelveInsight The growing demand for Ureteroscope Market is primarily attributed to the growing prevalence of urolithiasis or nephrolithiasis accompanied by the rising burden of obesity which is a risk factor for the development of kidney stones, and the entrance of key pharma players such as Olympus, Stryker, Boston Scientific Corporation, Richard Wolf GmbH, KARL STORZ in the Ureteroscope Market DelveInsight''s Ureteroscope Market Insights and Forecast report provides the current and forecast Ureteroscope, upcoming innovation in the devices, individual market shares of the devices, challenges, drivers and barriers, market trends, and key competitors in the Ureteroscope Market scenario. Some of the essential takeaways from the Ureteroscope Market report: According to DelveInsight analysis, North America is expected to dominate the overall Ureteroscope Market during the forecasted period.

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.

On CNBC’s “Halftime Report Final Trades,” Pete Najarian named Nvidia Corporation (NASDAQ: NVDA) as his pick, saying that options traders had bought more than 20,000 of the 260 calls that expire

The "Halftime Report" traders give their top picks to watch for the second half.

"Mad Money" host Jim Cramer explained Tuesday why he expects to see a bounce back in shares of Edwards Lifesciences, Intuitive Surgical and Stryker.

"I think there are some true steals are developing in the medical device space because of omicron," the "Mad Money" host said.

Despite pandemic-led disruptions, Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments.

Despite pandemic-led disruptions, Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments.

Stryker Corp (NYSE: SYK) posted Q4 adjusted EPS of $2.71, down 3.6% Y/Y, missing the consensus of $2.72. "We delivered a strong year of financial results, despite the ongoing challenges of the pande

Stryker (SYK) delivered earnings and revenue surprises of -0.37% and 1.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Stryker Corporation (SYK) CEO Kevin Lobo on Q4 2021 Results - Earnings Call Transcript

Stryker Corp. reported higher fourth-quarter profit and sales, but per-share earnings missed Wall Street's target.

Kalamazoo, Michigan, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2021: